Clinical trial · Interventional
Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Randomized Phase II Study of Combination Chemotherapy With Sildenafil Plus Carboplatin and Weekly Paclitaxel in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer
NCT00752115CI-TRIAL-00005456completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A comparison of combination chemotherapy of sildenafil plus carboplatin and weekly taxol with carboplatin and weekly taxol in patients with previously untreated advanced non-small cell lung cancer. The study hypothesis is that sildenafil may improve the distribution and efficacy of cytotoxic anticancer agents.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin (palaplatin) | Drug | Carboplatin | ALIAS |
| paclitaxel (taxol) | Drug | Paclitaxel | ALIAS |
| placebo | Drug | — | UNRESOLVED |
| sildenafil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- A
- description
- Sildenafil plus carboplatin and weekly paclitaxel
- interventionNames
- Drug: sildenafil
- Drug: paclitaxel (taxol)
- Drug: carboplatin (palaplatin)
- type
- PLACEBO_COMPARATOR
- label
- P
- description
- carboplatin and weekly paclitaxel
- interventionNames
- Drug: placebo
- Drug: paclitaxel (taxol)
- Drug: carboplatin (palaplatin)
Primary outcomes (1)
- measure
- progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer * Good performance status (ECOG 0-1) * No previous treatment * Adequate bone marrow, liver and renal functions * Must be able to swallow tablets * Provided written informed consent Exclusion Criteria: * Severe complications or a concomitant malignancy * Contraindicated sildenafil, carboplatin or taxol * Inappropriate patients for entry to this study, judged by the physicians
References
Publications (0)
Data not yet available
No reference posted for this study.